<DOC>
	<DOC>NCT00829257</DOC>
	<brief_summary>The purpose of this study is to establish whether addition of extra-fine particle steroid inhalers achieve additional suppression of small airways inflammation when added to 'standard' Fluticasone/Salmeterol combination therapy in refractory asthma.</brief_summary>
	<brief_title>Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Refractory, nonsmoking asthmatics with FEV1 les than 80% predicted RV greater than 100% predicted and CANO greater than 3ppb when stepped up to 1000Âµg of fluticasone per day, with or without additional asthma medication. Informed consent and ability to perform exhaled nitric oxide assessment. Participants must be on greater than 500mcg of fluticasone per day to enter dose ramp runin. Recent respiratory infection or oral steroid use. Pregnancy or lactation. Known or suspected contraindication to any of the IMP's. CANO less than 3ppb, FEV1 greater than 80% or RV less than 100% at postoptimisation visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>